Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

GLP-1 Therapy, Inflammation, and Anti-Aging Skin Health

Description

The talk explains how GLP-1 medications may benefit skin and overall aging by improving insulin sensitivity, reducing glycation, and lowering inflammation, while emphasizing that their effects are part of a broader, multifactorial approach. The speaker reviews the rise and mechanism of GLP-1s, their use in obesity and other conditions, and why they are being studied for inflammation-related diseases such as psoriasis, rheumatoid arthritis, and possibly wound healing. A major theme is that many visible skin issues—acne, rosacea, eczema, melasma, photoaging, puffiness, and even “Ozempic face” from rapid weight loss—are driven by inflammation, insulin resistance, hormone imbalance, poor diet, and loss of muscle or protein intake. Through multiple patient examples, the speaker shows that best results come from combining GLP-1s when appropriate with anti-inflammatory nutrition, adequate protein, exercise, hormone optimization, topicals, lasers, fillers, and other maintenance procedures. The message is that GLP-1s can be helpful, but thoughtful use, slow titration, and long-term lifestyle support are essential to preserve health, skin quality, and natural facial volume.

View more

Conclusions

GLP-1 receptor agonists may benefit skin primarily by improving insulin sensitivity, reducing glycation, and lowering inflammation rather than by directly acting as cosmetic anti-aging drugs.
The best dermatologic outcomes appear to come from combining GLP-1 therapy with diet, exercise, protein intake, hormones, sleep, and topical/procedural skin care.
Rapid weight loss on GLP-1s can produce facial volume loss, laxity, and the so-called “Ozempic face,” so slower weight loss and resistance training are important.
Many inflammatory skin and systemic conditions, including acne, rosacea, psoriasis, eczema, and autoimmune diseases, may improve when overall metabolic inflammation is reduced.
GLP-1s may indirectly support healthier skin healing and fibroblast activity, but evidence for direct dermatologic approval remains limited.
Weight loss and better glucose control can improve the appearance of skin by reducing inflammation and glycation-related aging changes.
Aging skin is strongly influenced by the interaction of hormones, insulin resistance, metabolism, and inflammatory state, especially in peri-menopausal and menopausal patients.
Patients using GLP-1s still need ongoing maintenance care, because lifestyle measures and aesthetic procedures remain necessary to preserve facial structure and skin quality.
GLP-1 therapy is promising for broader health and may help some inflammatory skin disease, but it should be used thoughtfully because side effects, muscle loss, dehydration, and rebound weight gain are real concerns.
The presentation’s overall conclusion is that patients are likely to be healthier and look better with a combined anti-inflammatory, metabolic, and aesthetic approach, with GLP-1s serving as one useful tool rather than the whole solution.